Can CBD Gummies Cause Psychosis? – Clinical Insights
CBD gummies psychosis clinical insights highlight the importance of patient screening and product quality. Emerging case reports raise questions about CBD's safety in vulnerable individuals. Clinicians must consider these insights when recommending…
Safety Alert: Cannabis Gummies Recalled for Unlabeled Soy Content
Cannabis gummies recall unlabeled soy highlights a critical patient safety issue for those with soy allergies. This recall underscores the importance of quality control in cannabis products. Patients should be vigilant about allergen information when…
Four Cannabis News Stories Worth Watching on September 5
Four cannabis news stories cover Colorado product safety, ATF medical-marijuana guidance, Arizona testing oversight, and Florida hemp timing. The shared theme is implementation, not proof of treatment benefit. Patients and clinicians should read each…
Virginia Hemp Testing Gaps Raise Patient Safety Questions
Virginia hemp testing gaps drew attention after one retail flower sample showed excess THC, microbes, and a pesticide. The finding is a patient-safety warning, not a statewide prevalence estimate. CED explains practical product checks and Virginia’s…
A Colorado Concentrate Passed Its Pesticide Test, Then Failed It. Two Weeks Later the Recall Doubled.
The Colorado marijuana recall 2026 involving Colorado's Best Dabs began on July 15 with a single concentrate batch and expanded on July 31 to add vaporizer cartridges, widen the sales window to August 1, 2025, and raise the store count from 11 to 24. The…
Congressional Amendments To Delay Or Speed Up Federal Hemp THC Product Ban Won’t …
Congressional amendments addressing federal hemp THC product regulation create clinical uncertainty for cannabis medicine practitioners and patients. The regulatory landscape directly impacts product quality, therapeutic consistency, and patient access…
Cannabis Products and Contaminant Detection: Critical Review of Regulatory Oversight and Analytical Methodologies.
A comprehensive review of cannabis contaminant testing regulatory inconsistencies reveals significant gaps in safety oversight across U.S. jurisdictions. This analysis highlights critical patient safety concerns stemming from variable testing standards…
GOP Lawmakers’ Hemp Amendments To The Farm Bill Would Allow Continued Legal Sales
The 2026 farm bill hemp amendments propose maintaining federal legal pathways for hemp-derived THC products. These amendments impact the legal sales and regulation of delta-8 and delta-10 THC. Clinicians face challenges due to product quality and safety…
Cannabis Health Studies Lag Behind Product Development, UMass Researchers Say – NEPM
The cannabis research gap highlights the disconnect between rapid product development and slower clinical studies. This gap affects patient safety and therapeutic outcomes. Clinicians face challenges making evidence-based recommendations due to limited…
Honest Paws vs Bailey’s CBD Reviews, Costs & Alternatives | ElleVet Sciences
Veterinary CBD product safety is a growing concern due to lack of FDA oversight and inconsistent formulations. This review compares Honest Paws and Bailey’s CBD products for pets. Understanding these differences helps clinicians advise pet owners…
